Literature DB >> 27187821

Leveraging antimicrobial stewardship into improving rates of carbapenem-resistant Enterobacteriaceae.

Darren Wong1, Brad Spellberg1,2.   

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) are among the most critical threats facing our healthcare system and account for significant patient mortality. There is considerable interest in the development of new treatment strategies. However, less attention has been paid to reducing CRE infection rates. Antibiotic stewardship programs can be uniquely empowered to reduce widespread pathogen resistance and by extension, optimize patient care and lower healthcare costs.

Entities:  

Keywords:  CRE; KPC; Klebsiella pneumnoniae carbapenemase; antibiotic stewardship

Mesh：

Substances：

Year:  2016        PMID： 27187821      PMCID： PMC5477703          DOI： 10.1080/21505594.2016.1188234

Source DB:  PubMed          Journal:  Virulence        ISSN： 2150-5594            Impact factor:   5.882


  37 in total

1.  First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America.

Authors:  Maria Virginia Villegas; Karen Lolans; Adriana Correa; Carlos Jose Suarez; Jaime A Lopez; Marta Vallejo; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

Authors:  Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi
Journal:  Clin Infect Dis       Date:  2016-04-13       Impact factor: 9.079

Review 3.  Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.

Authors:  Neil Gupta; Brandi M Limbago; Jean B Patel; Alexander J Kallen
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

4.  Hospital ward antibiotic prescribing and the risks of Clostridium difficile infection.

Authors:  Kevin Brown; Kim Valenta; David Fisman; Andrew Simor; Nick Daneman
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

5.  Clinicians' Attitudes Towards an Antimicrobial Stewardship Program at a Children's Hospital.

Authors:  Leslie M Stach; Erin B Hedican; Joshua C Herigon; Mary Anne Jackson; Jason G Newland
Journal:  J Pediatric Infect Dis Soc       Date:  2012-06-29       Impact factor: 3.164

6.  Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Amy L Pakyz; Michael Oinonen; Ronald E Polk
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

7.  Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

Authors:  Leanne B Gasink; Paul H Edelstein; Ebbing Lautenbach; Marie Synnestvedt; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-12       Impact factor: 3.254

8.  Regional dissemination of KPC-producing Klebsiella pneumoniae.

Authors:  Brandon Kitchel; Daniel R Sundin; Jean B Patel
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

9.  Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality.

Authors:  Mitchell J Schwaber; Shiri Klarfeld-Lidji; Shiri Navon-Venezia; David Schwartz; Azita Leavitt; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

10.  Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae.

Authors:  Sandeep Kochar; Timothy Sheard; Roopali Sharma; Alan Hui; Elaine Tolentino; George Allen; David Landman; Simona Bratu; Michael Augenbraun; John Quale
Journal:  Infect Control Hosp Epidemiol       Date:  2009-05       Impact factor: 3.254
View more
  6 in total

1.  Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know.

Authors:  David van Duin
Journal:  Virulence       Date:  2017-04-12       Impact factor: 5.882

Review 2.  Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy.

Authors:  Darren Wong; David van Duin
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

3.  Effects of Regulation on Carbapenem Prescription in a Large Teaching Hospital in China: An Interrupted Time Series Analysis, 2016-2018.

Authors:  Lewei Xie; Yaling Du; Xuemei Wang; Xinping Zhang; Chenxi Liu; Junjie Liu; Xi Peng; Xinhong Guo
Journal:  Infect Drug Resist       Date:  2021-08-11       Impact factor: 4.003

4.  Descriptive analysis of infections due to New Delhi metallo-β-lactamase-producing Enterobacterales in children at Red Cross War Memorial Children's Hospital.

Authors:  Leonore Greybe; James J C Nuttall; Adrian J Brink; Hafsah D Tootla
Journal:  S Afr J Infect Dis       Date:  2022-07-27

Review 5.  Applying Diagnostic Stewardship to Proactively Optimize the Management of Urinary Tract Infections.

Authors:  Faiza Morado; Darren W Wong
Journal:  Antibiotics (Basel)       Date:  2022-02-24

6.  Implementation of an antimicrobial stewardship programme and reduction in carbapenemase-producing Enterobacterales in an Australian local health district.

Authors:  Kimberly Cipko; Jose Cuenca; Erica Wales; Joanna Harris; Stuart Bond; Peter Newton; Spiros Miyakis
Journal:  JAC Antimicrob Resist       Date:  2020-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.